Lilly files suit over flea medication sales from Australia
The Indianapolis-based pharmaceutical firm claims an Australian veterinary clinic is infringing on its Comfortis flea medication’s trademark by reselling it to U.S. consumers online.
Patent
Articles
Zyprexa era comes to an end for Lilly
On Oct. 24, the U.S. Food and Drug Administration approved the first generic versions of Eli Lilly and Co.’s best-seller, ending 15 years of highly lucrative sales.
BorgWarner sues Cummins over patents on turbochargers
BorgWarner Inc., the world’s biggest maker of automatic-transmission parts for vehicles, filed a lawsuit accusing Cummins Inc. of infringing on three patents for a titanium wheel used in engine turbochargers.
Lilly: Vendors key after Zyprexa patent loss
Lilly’s patent-loss challenges—the biggest of which takes effect today—will force the company to rely even more on its 1,300 Indiana vendors.
Sweeping reform to patent system signed into law
The first significant change in patent law since 1952 is designed to ease the way for inventors to bring products to market and help whittle down a massive backlog of applications.
Critics: Patent overhaul could hurt startups
When the Senate passed legislation last week overhauling the U.S. patent system, large multinational corporations like Eli Lilly and Co. rejoiced. But small-business advocates cried foul, saying the changes would put innovative startups at a disadvantage.
Senate passes overhaul of patent system
The legislation would fundamentally alter the way patents are reviewed and mark the biggest change to U.S. patent law since at least 1952.
Despite sales spike, Effient has middling prospects
Remember Effient? The blood thinner that was once Eli Lilly and Co.’s greatest post-Zyprexa hope and then, after a slow launch, was dismissed as an abject failure? Well, it’s turning out to defy both predictions.
Lilly CEO: Immigration, tax laws slow innovation
The U.S. government needs to open its borders to attract and retain talented scientists for drugmakers to employ, Eli Lilly & Co. CEO John Lechleiter plans to tell a technology conference Thursday.
Growth in drug spending to slow as generics rise
The annual growth rate in spending on drugs may be cut in half over the next five years as people opt for less expensive generic medicines over brand-name treatments, a health-care research group said Wednesday, highlighting the challenge pharmaceutical firms like Eli Lilly and Co. are facing.
Court blocks generic versions of Lilly’s Cymbalta
Eli Lilly and Co. said Wednesday that a federal court is blocking low-cost generic versions of Cymbalta from the market until the patents supporting the drug expire.
Zimmer, peer sued over arthritic-knee treatments
Genzyme Corp., the drugmaker bought by Sanofi-Aventis SA this month, sued Zimmer Holdings Inc. and Anika Therapeutics Inc. alleging the companies’ treatments for arthritic knee pain infringe a patent.
Firm joins race with IU autism drug
The Indiana University School of Medicine has licensed a pediatric psychiatrist’s patent on
an alcohol-dependency drug that the doctor discovered improves the language and social skills of autism patients. IU has licensed the patent to Indianapolis-based Confluence Pharmaceuticals Inc.
Lechleiter: After the deluge, we’ll be fine
Eli Lilly and Co. CEO John Lechleiter visited Japan last week—three days before the massive earthquake—to deliver his tried-and-true message: Drug companies need to reinvent invention, governments needs to support innovation, and Lilly will be just fine after it has sustained the damage of the next three years.
Dow Chemical moves toward engineered corn patent
Dow Chemical Co.'s agricultural division said it has taken the next step toward gaining international patent rights for its new strain of genetically engineered corn that it says will help farmers battle a new strain of “super-weeds.”
Congress takes up major change in patent law
Congress has been trying for well over a decade to rewrite patent law, only to be thwarted by the many interested parties.
Intellectual property theft rising quickly
Filching ranges from crude to highly sophisticated, experts say.
Emerging markets give Lilly hope in patent crunch
In a kind of alternate drug universe, sales of Eli Lilly and Co.’s ghosts of blockbusters past are soaring in China—prompting the drugmaker to pour money into emerging markets in an attempt to prop up revenue.
Vanderbilt rejected by high court on Cialis patents
Supreme Court justices on Monday left intact a ruling throwing out a lawsuit pressed by the Nashville, Tenn., university against Eli Lilly’s Icos subsidiary.
Eli Lilly puts faith in drug pipeline
Eli Lilly and Co. started to tip over its massive “patent cliff” this year, yet announced little publicly that will significantly soften its inevitable sales plunge.